Asked by: Julian Smith (Conservative - Skipton and Ripon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will meet with the Lobular Moon Shot Project to discuss funding for lobular breast cancer research.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £133 million in 2023/24 reflecting its high priority.
We are proud to have invested £29 million into the Institute of Cancer Research (ICR) and the Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, including lobular breast cancer. Wider investments into breast cancer research include a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, including lobular breast cancer.
On 4 February 2025 the Department announced that almost 700,000 women across the country will take part in a world-leading trial to test how cutting-edge artificial intelligence (AI) tools can be used to catch breast cancer cases earlier. The Early Detection using Information Technology in Health (EDITH) trial is backed by £11 million of Government support via the NIHR.
The NIHR continues to encourage and welcome funding applications for research into any aspect of human health, including lobular breast cancer. Improving outcomes for people with cancer is a priority for the Government.
Asked by: Helen Hayes (Labour - Dulwich and West Norwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the total amount of research funding spent on lobular breast cancer research was in 2023- 2024.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £133 million in 2023/24, reflecting its high priority.
We are proud to have invested £29 million into the Institute of Cancer Research and the Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, including lobular breast cancer. Wider investments into breast cancer research include a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, including lobular breast cancer.
On 4 February 2025 the Department announced that nearly 700,000 women across the country will take part in a world-leading trial to test how cutting-edge artificial intelligence tools can be used to catch breast cancer cases earlier. The Early Detection using Information Technology in Health trial is backed by £11 million of Government support via NIHR. The NIHR continues to encourage and welcome funding applications for research into any aspect of human health, including lobular breast cancer.
Asked by: Helen Hayes (Labour - Dulwich and West Norwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the total amount of research funding spent on lobular breast cancer research was in 2022- 2023.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £133 million in 2023/24, reflecting its high priority.
We are proud to have invested £29 million into the Institute of Cancer Research and the Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, including lobular breast cancer. Wider investments into breast cancer research include a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, including lobular breast cancer.
On 4 February 2025 the Department announced that nearly 700,000 women across the country will take part in a world-leading trial to test how cutting-edge artificial intelligence tools can be used to catch breast cancer cases earlier. The Early Detection using Information Technology in Health trial is backed by £11 million of Government support via NIHR. The NIHR continues to encourage and welcome funding applications for research into any aspect of human health, including lobular breast cancer.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what funding her Department has provided to the Lobular Moonshot Project.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests £1.5 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £133 million in 2023/24, reflecting its high priority.
We are proud to have invested £29 million into the Institute of Cancer Research (ICR) and the Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, including lobular breast cancer. Wider investments into breast cancer research include a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, including lobular breast cancer.
On 4 February 2025, the Department announced that almost 700,000 women across the country will take part in a world-leading trial to test how cutting-edge artificial intelligence tools can be used to catch breast cancer cases earlier. The Early Detection using Information Technology in Health trial, also known as EDITH, is backed by £11 million of Government support via the NIHR.
The NIHR continues to encourage and welcome funding applications for research into any aspect of human health, including lobular breast cancer.
Asked by: Melanie Ward (Labour - Cowdenbeath and Kirkcaldy)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, if he will hold discussions with the Manchester Breast Centre on the potential merits of providing additional support for their research into lobular breast cancer.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
Cancer research is a critical priority for the Government. The Government does not ringfence funding for specific cancer types but is committed to supporting cancer research such as that conducted at Manchester Breast Centre. The Department for Science, Innovation and Technology invests approximately £200 million into cancer research annually via UK Research and Innovation, and The Department of Health and Social Care spent £121.8 million in 2022/23 on cancer research through the National Institute for Health and Care Research. The Department of Health and Social Care is currently engaging with the sector to develop a new National Cancer Plan which will outline the Government’s strategy to improve outcomes for cancer patients, including lobular breast cancer.
Asked by: Helen Hayes (Labour - Dulwich and West Norwood)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what estimate his Department has made of the total level of funding allocated by the Medical Research Council into specific research on the (a) diagnosis and (b) treatment of lobular breast cancer in each of the last five years.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Government does not ringfence funding for specific cancers. DSIT invests approximately £200 million into cancer research annually via UK Research and Innovation, including the Medical Research Council (MRC). The average annual funding awarded by UKRI to breast cancer research (including diagnosis and treatment) between 2018 and 2022 was approximately £10 million. The MRC invests approximately £125 million into cancer annually. DHSC spent £121.8 million in 2022/23 on cancer research via the National Institute for Health and Care Research (NIHR). NIHR research infrastructure funding supports Biomedical Research Centres and the NIHR Research Delivery Network, which has enabled the delivery of 10 lobular breast cancer studies.
Asked by: Neil Duncan-Jordan (Labour - Poole)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans he has to meet with the leadership of the Lobular Moon Shot Project to discuss funding.
Answered by Andrew Gwynne
The Department invests £1.5 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £133 million in 2023/24 reflecting its high priority.
There are no current plans to meet with the leadership of the Lobular Moon Shot Project to discuss funding. Officials meet regularly with partners to discuss research investments and priorities.
We are proud to have invested £29 million into the Institute of Cancer Research and the Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, including lobular breast cancer. Wider investments into breast cancer research include a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, including lobular breast cancer.
NIHR welcomes funding applications for research into any aspect of human health, including into lobular breast cancer. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.
Asked by: John Milne (Liberal Democrat - Horsham)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what steps he is taking with Cabinet colleagues to fund research into lobular breast cancer.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Government doesn’t ringfence funding for specific diseases but is committed to funding cancer research, including lobular breast cancer. The Department of Health and Social Care spent £121.8 million in 2022/23 on cancer research through the National Institute for Health and Care Research.
The Department for Science, Innovation and Technology funds cancer research via UK Innovation and Research (UKRI). UKRI invests approximately £200 million annually into cancer research, of which £10m per year is for breast cancer research.
Office for Life Sciences’ Cancer Healthcare Goals programme funds innovations at the earlier stages of the research and development pipeline. Such innovations will have the potential to diagnose multiple tumour types, including breast cancer.
We have allocated £1.3 million of funding for a National Institute of Health and Care Research (NIHR) project that will assess the effectiveness of a new form of MRI scan to detect breast cancers that have been missed by mammograms.
Further NIHR research infrastructure funding supports Biomedical Research Centres and the NIHR Research Delivery Network, which has enabled delivery of 10 lobular breast-cancer studies.
Asked by: John Milne (Liberal Democrat - Horsham)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, if he will meet with Dr Susan Michaelis to discuss funding of research into invasive lobular breast cancer.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Department for Science, Innovation and Technology (DSIT) and Office for Life Sciences Officials have met with Dr Michaelis to discuss lobular breast cancer. The Government does not ringfence funding for specific cancer types. DSIT invests approximately £200 million into cancer research annually via UK Research and Innovation, and The Department of Health and Social Care (DHSC) spent £121.8 million in 2022/23 on cancer research through the National Institute for Health and Care Research. DHSC is currently developing a new National Cancer Plan which will outline the Government’s strategy to improve patient outcomes for all cancer types, including breast cancer.
Asked by: Melanie Ward (Labour - Cowdenbeath and Kirkcaldy)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with the Secretary of State for Science, Innovation and Technology on research into lobular breast cancer.
Answered by Andrew Gwynne
Cancer research is a critical priority for the Department of Health and Social Care, the Department of Science, Innovation and Technology, and their operational delivery partners, like the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC). Department of Health and Social Care and Department of Science, Innovation and Technology officials meet regularly to discuss a range of research investments, including lobular and other breast cancers, to drive the maximum collective research impact on policy, practice, and individual lives.
The Department invests £1.5 billion each year on research through its research delivery arm, the NIHR. The NIHR spends more on cancer than any other disease group, at over £121.8 million in 2022/23, reflecting its high priority. The NIHR awarded funding to 53 new research projects on breast cancer in the period 2018/19 to 2022/23, to a total value of £31 million.
Cancer is also one of the largest areas of investment for the MRC with an annual spend of approximately £125 million, including investment in the Francis Crick Institute. In addition, other parts of UK Research and Innovation (UKRI) spend approximately £75 million annually. Over five years, between 2018 and 2022, the average funding awarded by UKRI, including the MRC, to breast cancer research was approximately £10 million per year.